2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
July 19, 2018

Oncobiologics Completes Exchange of Series A Convertible Preferred Stock for Newly Created Series A-1 Convertible Preferred Stockmore >

July 11, 2018

Oncobiologics Regains Compliance with Applicable Nasdaq Listing Requirementsmore >

June 20, 2018

Oncobiologics Announces Conversion of Majority of Series A Convertible Preferred Stockmore >

June 18, 2018

Oncobiologics Announces Randy Thurman as Executive Chairman of the Board of Directors and Lawrence A. Kenyon as Interim CEOmore >

June 13, 2018

Oncobiologics Enters into First CDMO Contractmore >

June 08, 2018

Oncobiologics Closes Second Tranche of $15 Million Private Placementmore >

June 04, 2018

Stelis Biopharma and Oncobiologics to Unveil Bio2Source CDMO Offering at BIO 2018more >

May 15, 2018

Oncobiologics Reports Second Quarter Financial Results for Fiscal 2018more >

May 14, 2018

Oncobiologics Announces $15 Million Private Placement Offeringmore >

April 17, 2018

Oncobiologics Appoints Randy Thurman to Board of Directorsmore >

March 27, 2018

Oncobiologics Appoints Dr. Joerg Windisch to Board of Directorsmore >

February 14, 2018

Oncobiologics Reports First Quarter Fiscal Year 2018 Resultsmore >

February 13, 2018

Oncobiologics Receives Positive Nasdaq Listing Determinationmore >

February 09, 2018

Oncobiologics Announces Term Extension of Series A Warrantsmore >